Nautilus Biotechnology (NAUT) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
17 Jun, 2026Opening remarks and agenda
The meeting was called to order by the CEO, who introduced the board members, corporate officers, auditors, legal counsel, and inspector of election present virtually.
The agenda included formal business, voting on proposals, and a Q&A session with stockholders.
Corporate governance
Notice of the meeting and proxy materials were mailed to all stockholders of record, and proof of mailing was filed with the meeting minutes.
A quorum was confirmed, allowing the meeting to proceed with voting on all matters.
Voting was conducted virtually and by proxy, with each share entitled to one vote.
Board and executive committee updates
Two Class II directors were up for election, with nominations closed as no additional candidates were proposed by stockholders.
The board consists of seven directors divided into three classes with staggered terms.
Latest events from Nautilus Biotechnology
- A novel proteomics platform promises to revolutionize drug discovery and precision medicine.NAUT
Investor Summit Virtual Conference2 May 2026 - Board recommends all proposals, annual say-on-pay, and highlights strong governance and compliance.NAUT
Proxy filing28 Apr 2026 - Operating expenses fell 14% and net loss narrowed as commercialization and early access expanded.NAUT
Q1 202628 Apr 2026 - Annual meeting to elect directors, ratify auditor, and vote on executive pay and its frequency.NAUT
Proxy filing28 Apr 2026 - New proteomics platform promises comprehensive, reproducible protein analysis with broad applications.NAUT
TD Cowen 46th Annual Health Care Conference2 Mar 2026 - Operating expenses and net loss declined, with commercial launch and revenue ramp set for 2027.NAUT
Q4 202526 Feb 2026 - Q2 net loss reached $18M as platform development advanced and 2025 launch remained on track.NAUT
Q2 20242 Feb 2026 - 2025 launch targets deep, accessible proteomics with strong market and customer momentum.NAUT
Goldman Sachs 45th Annual Global Healthcare Conference1 Feb 2026 - Comprehensive, high-sensitivity proteomics platform targets 2025 launch with robust financials.NAUT
Morgan Stanley 22nd Annual Global Healthcare Conference22 Jan 2026